Oncotarget

Research Papers:

Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells

Pauline Adjibade _, Valerie Grenier St-Sauveur, Miguel Quevillon-huberdeau, Marie Josée Fournier, Andreanne Savard, Laetitia Coudert, Edouard W Khandjian and Rachid Mazroui

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:43927-43943. https://doi.org/10.18632/oncotarget.5980

Metrics: HTML 1073 views  |   ?  


Abstract

Pauline Adjibade1,2,3, Valérie Grenier St-Sauveur1,2,3, Miguel Quevillon Huberdeau1,2,3, Marie-Josée Fournier1,2,3, Andreanne Savard1,2,3, Laetitia Coudert1,2,3, Edouard W. Khandjian4,5, Rachid Mazroui1,2,3

1Centre de Recherche du toCHU de Québec, Université Laval, Québec, PQ, Canada

2Département de Biologie Moléculaire, Biochimie Médicale et Pathologie, Faculté de Médecine, Université Laval, Québec, PQ, Canada

3Centre de Recherche en Cancérologie de l’Université Laval, Université Laval, Québec, PQ, Canada

4Centre de Recherche, Institut Universitaire en Santé Mentale de Québec, Université Laval, Québec, PQ, Canada

5Département de Psychiatrie et de Neurosciences, Faculté de Médecine, Université Laval, Québec, PQ, Canada

Correspondence to:

Rachid Mazroui, e-mail: rachid.mazroui@crsfa.ulaval.ca

Keywords: stress granules, sorafenib, PERK, eIF2a, ATF4

Received: July 13, 2015     Accepted: October 04, 2015     Published: November 02, 2015

ABSTRACT

Stress granules (SGs) are cytoplasmic RNA multimeric bodies that form under stress conditions known to inhibit translation initiation. In most reported stress cases, the formation of SGs was associated with the cell recovery from stress and survival. In cells derived from cancer, SGs formation was shown to promote resistance to either proteasome inhibitors or 5-Fluorouracil used as chemotherapeutic agents. Despite these studies, the induction of SGs by chemotherapeutic drugs contributing to cancer cells resistance is still understudied. Here we identified sorafenib, a tyrosine kinase inhibitor used to treat hepatocarcinoma, as a potent chemotherapeutic inducer of SGs. The formation of SGs in sorafenib-treated hepatocarcionoma cells correlates with inhibition of translation initiation; both events requiring the phosphorylation of the translation initiation factor eIF2α. Further characterisation of the mechanism of sorafenib-induced SGs revealed PERK as the main eIF2α kinase responsible for SGs formation. Depletion experiments support the implication of PERK-eIF2α-SGs pathway in hepatocarcinoma cells resistance to sorafenib. This study also suggests the existence of an unexpected complex regulatory balance between SGs and phospho-eIF2α where SGs dampen the activation of the phospho-eIF2α-downstream ATF4 cell death pathway.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5980